| 06th week of 2014 patent applcation highlights part 56 |
| Patent application number | Title | Published |
|---|
| 20140038899 | BIOMARKERS FOR OVARIAN CANCER - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry. | 2014-02-06 |
| 20140038900 | DOMINANT NEGATIVE HSP110 MUTANT AND ITS USE IN PROGNOSING AND TREATING CANCERS - The present invention relates to a mutated heat-shock protein 110 (HSP110) lacking its substrate binding domain, which does not exhibit its chaperone activity and/or is not capable of binding to heat-shock protein 70 (HSP70) and/or to heat-shock protein 27 (HSP27), but which is capable of binding to a wild-type HSP 110. Such a mutated heat-shock protein 110 can be used (i) in methods for prognosing survival and/or the response to a treatment of a patient suffering from a cancer, more particularly from a cancer liable to have a microsatellite instability (MSI) phenotype, such as colorectal cancer (CRC), and (ii) for treating cancers. | 2014-02-06 |
| 20140038901 | CIRCULATING EXOSOMES AS DIAGNOSTIC/PROGNOSTIC INDICATORS AND THERAPEUTIC TARGETS OF MELANOMA AND OTHER CANCERS - The present invention is directed to methods of diagnosing, preventing, and treating metastatic disease in a subject. The present invention is also directed to a method of inhibiting primary tumor growth in a subject. Methods of identifying candidate compounds useful for preventing and treating metastatic disease and primary tumor growth in a subject are also disclosed. | 2014-02-06 |
| 20140038902 | Method of Treating Metastatic Cancer - A method of treating metastatic cancer, comprising the steps of (a) treating a metastatic cancer patient with an isolated therapeutic Cystatin C peptide, and (b) observing a reduction in tumor burden is disclosed. | 2014-02-06 |
| 20140038903 | Selective Cysteine Protease Inhibitors and Uses Thereof - The present invention relates to compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteases. Also described are methods where the compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 are used in the prevention and/or treatment of various diseases and conditions in subjects, including cysteine protease-mediated diseases and/or caspase-mediated diseases such as sepsis, myocardial infarction, cancer, tissue atrophy, ischemia, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative diseases such as multiple sclerosis (MS), ALS, Alzheimer's disease, Parkinson's disease, and Huntington's disease). | 2014-02-06 |
| 20140038904 | PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN - Therapeutic methods are disclosed herein. | 2014-02-06 |
| 20140038905 | PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN - Therapeutic methods are disclosed herein. | 2014-02-06 |
| 20140038906 | THERAPEUTIC AND DIAGNOSTIC METHODS INVOLVING BIGLYCAN AND UTROPHIN - The present disclosure provides methods for predicting a patient's response to biglycan therapy for diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of such diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. This application also provides combination therapeutics, such as a biglycan therapeutic and a utrophin therapeutic. | 2014-02-06 |
| 20140038907 | Coatings For Implantable Medical Devices - The present application teaches a coating having a biologically compatible compound conjugated to, or blended with, a polymer, wherein the polymer includes at least one olefin-derived unit and at least one unit derived from a vinyl alcohol, an allyl alcohol, or derivatives thereof. | 2014-02-06 |
| 20140038908 | Polynucleotides and Polypeptides Associated with Trophoblast Cell Death, Differentiation, Invasion and/or Cell Fusion and Turnover - The invention relates to polypeptides and polynucleotides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, and uses of same in the prevention, diagnosis and treatment of conditions requiring regulation of trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover. In particular aspects, diagnostic methods are disclosed for evaluating conditions such as preeclampsia utilizing matador polypeptides and polynucleotides encoding same. | 2014-02-06 |
| 20140038909 | TISSUE OCCLUDING AGENT - There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. | 2014-02-06 |
| 20140038910 | Beta Amino Acid Derivatives as Integrin Antagonists - Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: | 2014-02-06 |
| 20140038911 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to a pharmaceutical composition according to the claim | 2014-02-06 |
| 20140038912 | ADENOSINE ANALOGS AND THEIR USE - Provided are adenosine analog compounds of the general formula that act as P2Y receptors, e.g., the P2Y | 2014-02-06 |
| 20140038913 | LUTEOLIN AND DIOSMIN/DIOSMETIN AS NOVEL STAT3 INHIBITORS FOR TREATING AUTISM - The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation. | 2014-02-06 |
| 20140038914 | COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION - This invention relates to a compound of Formula 1A: | 2014-02-06 |
| 20140038915 | METHODS FOR TREATING BACTERIAL INFECTION - This invention relates to methods for treating bacterial infection, which methods find utility in the treatment of, for example, infected ulcers, optionally infected diabetic ulcers. In particular, this invention relates to treating bacterial infection, for example, infected diabetic ulcers by topical administration of at least one aminoglycoside antibiotic at the site of infection, in combination with at least one antibacterial agent, which antibacterial agent is administered remote from the site of infection, preferably administered systemically. In a particular embodiment, the present invention relates to a composition for use in treating bacterial infection, the composition comprising gentamicin sulphate (a water-soluble broad-spectrum aminoglycoside antibiotic) uniformly dispersed in a type-I collagen matrix; incombination with at least one systemically-administered antibacterial agent. The present invention provides bactericidal activity against most strains of aerobic gram-negative and gram-positive and facultative anaerobic gram-negative pathogens, including methicillin-resistant | 2014-02-06 |
| 20140038916 | O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE - This application discloses novel phosphoramidate and phosphonoamidate prodrugs of nucleosides, nucleotides, C-nucleosides, C-nucleotides, phosphonates, and other alcohol-containing drugs; use of these prodrugs for treatment of infectious diseases and cancers, in particular, liver infections and cancers; and methods of preparing these novel phosphoramidate and phosphonoamidate prodrugs. | 2014-02-06 |
| 20140038917 | STERILE AND INJECTABLE AQUEOUS FORMULATION FOR ADMINISTRATION IN THE INTRA-ARTICULAR SPACE OF AN INTRA-ARTICULAR JOINT - The present invention relates generally to the treatment and/or prevention of pain associated with an intra-articular joint degeneration or disease. This invention concerns in particular a sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint of a subject, in the form of a gel. | 2014-02-06 |
| 20140038918 | TREATMENTS FOR RETINAL DISORDERS - The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy. | 2014-02-06 |
| 20140038919 | HEPATITIS C INHIBITORS AND USES THEREOF - This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 2014-02-06 |
| 20140038920 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF - The invention refers to TFEB phosphorylation inhibitors. Such molecules have a therapeutic applicability in all disorders that need induction of the cell authophagic/lysosomal system, such as lysosomal storage disorders, neurodegenerative diseases, hepatic diseases, muscle diseases and metabolic diseases. | 2014-02-06 |
| 20140038921 | NEW LOW SIDE EFFECT PHARMACEUTICAL COMPOSITION CONTAINING ANTITUBERCULOSIS DRUGS - A pharmaceutical composition for treating tuberculotic diseases with no side effect/low side effect is provided by the present invention, which pharmaceutically effective amount of one or more compounds chosen from isoniazid, rifampin, pyrazinamide and ethambutol, and pharmaceutically effective amount of substances which can reduce the side effect of the antituberculosis agents. | 2014-02-06 |
| 20140038922 | WNT PROTEIN SIGNALLING INHIBITORS - The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis. | 2014-02-06 |
| 20140038923 | PYRAZOLE INHIBITORS OF COX-2 AND SEH - The present invention provides compounds and compositions, e.g., a series of compounds wherein a 1,5-biarylpyrazole group is conjugated to a urea group by a non-cleavable covalent chain, that are useful as dual COX-2/sEH inhibitors. The compounds disclosed herein have activity associated with the arachidonate cascade. The activity of these compounds was demonstrated using a lipopolysaccharide (LPS) induced model of pain in the rat. The compounds of the present invention demonstrated superior anti-allodynic activity as compared to the same dose of celecoxib, i.e., a COX-2 inhibitor, also as compared to the same dose of t-AUCB, i.e., a sEH inhibitor, and also as compared to the co-administered same dose of both celecoxib and t-AUCB. The dual inhibitors of the present invention demonstrate enhanced in vivo anti-allodynic activity in a nociceptive behavioral assay. In addition, the compounds of the present invention also demonstrated to have potent anti-angiogenic effects toward endothelial cells (HUVEC) and inhibit angiogenesis in vitro, ex vivo and in vivo. The dual inhibitors of the present invention also demonstrate anti-angiogenic effect to slow breast tumor growth in vivo. | 2014-02-06 |
| 20140038924 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 2014-02-06 |
| 20140038925 | Novel Vitamin D Receptor Modulators with Partial Agonist Activity - The present invention provides a compound which functions as a selective vitamin D receptor modulator and has action-selectivity or tissue-selectivity such that it does not induce hypercalcemia but causes other effects. There is provided a compound represented by formula (I), a solvate thereof or a prodrug thereof. | 2014-02-06 |
| 20140038926 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators - The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 2014-02-06 |
| 20140038927 | COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS - The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury. | 2014-02-06 |
| 20140038928 | 5-(2--1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES - The present invention provides a compound which is a hydroxyquinolinone derivative of formula (I), | 2014-02-06 |
| 20140038930 | ANDROGEN TREATMENT IN FEMALES - Method of using an androgen, such as dehydroepiandrosterone (DHEA) or testosterone, to improve human folliculogenesis. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of the androgen per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of an androgen per day to the female for at least four months. | 2014-02-06 |
| 20140038931 | METHOD FOR PRODUCING A COMPOSITE ORGANIC COMPOUND POWDER FOR MEDICAL USE - The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. | 2014-02-06 |
| 20140038932 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 2014-02-06 |
| 20140038933 | Composition and Method For Preventing Discoloration of Pyrithione Containing Compositions - The present invention provides a composition containing a pyrithione compound and a pyranone compound and a method of reducing discoloration of compositions containing pyrithione compounds. The composition may be a soap composition. | 2014-02-06 |
| 20140038934 | MODULATORS OF SEROTONIN RECEPTORS - Certain biphenyl compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases. | 2014-02-06 |
| 20140038935 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2014-02-06 |
| 20140038936 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2014-02-06 |
| 20140038937 | Chromenone Derivatives - The invention concerns chromenone compounds of Formula I; | 2014-02-06 |
| 20140038938 | Substituted dihydropyrazolones and their use - The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing. | 2014-02-06 |
| 20140038939 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS - A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R | 2014-02-06 |
| 20140038940 | NOVEL EGFR MODULATORS AND USES THEREOF - The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways. | 2014-02-06 |
| 20140038941 | RING-FUSED HETEROCYCLIC DERIVATIVE - A ring-fused heterocyclic derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof having a T-type calcium channel regulatory effect and useful as a pruritus therapeutic and/or preventive agent, and the like are provided. In the general formula (I), R | 2014-02-06 |
| 20140038942 | RORgammaT INHIBITORS - The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition. | 2014-02-06 |
| 20140038943 | SEROTONIN RECEPTOR MODULATOR - Certain biphenyic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases. | 2014-02-06 |
| 20140038944 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS - A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, | 2014-02-06 |
| 20140038945 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF - The invention includes a compound of formula I: | 2014-02-06 |
| 20140038946 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS - The disclosure relates to (heterocycle-fused piperidine)-(piperazinyl)-1-alkanone derivatives and (heterocycle-fused pyrrolidine)-(piperazinyl)-1-alkanone derivatives of formula (I): | 2014-02-06 |
| 20140038947 | THERAPEUTIC APPLICATIONS OF PRO-APOPTOTIC BENZODIAZEPINES - Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of structures: | 2014-02-06 |
| 20140038948 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. | 2014-02-06 |
| 20140038949 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE - The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided. | 2014-02-06 |
| 20140038950 | PLANT TREATMENT - An anti-fungal treatment for trees and bushes. Included are all methods of delivery of active ingredients, including foliar and trunk spraying application, granular soil surface, soil drench, soil injection, and trunk injection. The chemical combination includes a group 3 fungicide like propiconazole, that is, a systemic with curative and protective action, that works via the demethylation of C-14 during ergosterol biosynthesis. The combination also includes a group 11 fungicide like Azoxystrobin, or Fluoxastrobin for which their biochemical mode of action is inhibition of electron transport. The combined efficacy of there two classes of chemicals is reduced spreading of the fungus and increased killing of fungus. It has also been found that these chemicals used individually on trees and bushes, have unexpected benefits. | 2014-02-06 |
| 20140038951 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS - Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same. | 2014-02-06 |
| 20140038952 | Substituted Amino-Pyrimidine Derivatives - The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer. | 2014-02-06 |
| 20140038953 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE - The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to reduce circulating levels of ApoB-100 or LDL. These compounds may also be used to treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia. | 2014-02-06 |
| 20140038954 | Spiro-Amino-Imidazo-Fused Heterocyclic Compounds as Beta-secretase Modulators and Methods of Use - The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I, wherein variables A | 2014-02-06 |
| 20140038955 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS - Heteroaryl amide analogues are provided, of the Formula: | 2014-02-06 |
| 20140038956 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc). - The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs. | 2014-02-06 |
| 20140038957 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES - This invention relates to pyrrolopyrimidine derivatives of formula (I): where R | 2014-02-06 |
| 20140038958 | CDK8-CDK19 SELECTIVE INHIBITORS AND THEIR USE IN ANTI-METASTATIC AND CHEMOPREVENTATIVE METHODS FOR CANCER - The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient. | 2014-02-06 |
| 20140038959 | METHODS OF TREATING TUMORS - The present invention relates to a method of treating tumors wherein PAK1 is over-expressed or amplified by co-administering a PAK1 inhibitor and a second anti-hyper-proliferative agent | 2014-02-06 |
| 20140038960 | Hetaryl-[1,8]naphthyridine derivatives - Novel hetaryl-[1,8]naphthyridine derivatives of formula (I) | 2014-02-06 |
| 20140038961 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES - The invention relates to 3-ureidoisoquinolin-8-yl derivatives of formula I | 2014-02-06 |
| 20140038962 | Flavivirus Inhibitors and Methods of Their Use - Methods of treating, preventing, and/or ameliorating a | 2014-02-06 |
| 20140038963 | Multifunctional Radical Quenchers For The Treatment Of Mitochondrial Dysfunction - The present disclosure provides methods for identifying therapeutic agents that are multifunctional radical quenchers. It also provides compounds of formula (I), (II), or (II-A): and pharmaceutically acceptable salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of diseases associated with decreased mitochondrial function resulting in diminished ATP production and/or oxidative stress and/or lipid peroxidation. | 2014-02-06 |
| 20140038964 | IMIDAZOLE BASED LXR MODULATORS - Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId | 2014-02-06 |
| 20140038965 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS - 5- and 6-membered heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Also described is the treatment of neurological, neurodegenerative and psychiatric disorders including but not limited to those comparing cognitive deficits or schizophrenic symptoms. | 2014-02-06 |
| 20140038966 | TEGAFUR-CONTAINING COMPOSITION FOR SINGLE DAILY AND ALTERNATE-DAY DOSING - This invention provides an antitumor agent comprising a combination drug containing tegafur, gimeracil, and oteracil potassium, characterized by being repeatedly administered to a patient once a day every other day, four days a week, at a dose such that the tegafur is administered in an amount of 80 mg or more/dose when the patient has a body surface area of less than 1.25 m | 2014-02-06 |
| 20140038967 | NOVEL USE FOR IMIDAZOTRIAZINONES - Provided herein are compounds for use in the treatment of central nervous system (CNS)-trauma related disorders like spinal cord injuries. Pharmaceutical compositions, single unit dosage forms, and kit suitable for use for the treatment of (CNS)-trauma related disorders are also disclosed. | 2014-02-06 |
| 20140038968 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS - The present invention relates to certain novel compounds of Formula (I): | 2014-02-06 |
| 20140038969 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (VIII): | 2014-02-06 |
| 20140038970 | BRIDGED AND FUSED ANTIDIABETIC COMPOUNDS - This invention provides for certain bridged and fused compounds of the formula | 2014-02-06 |
| 20140038971 | SUBSTITUTED TETRAZOL-1-YL-PHENOXYMETHYL-THIAZOL-2-YL-PIPERIDINYL-PYRIMIDINE SALTS - Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed. | 2014-02-06 |
| 20140038972 | ALPHA-2 AGONIST POLYMERIC DRUG DELIVERY SYSTEMS - Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure. | 2014-02-06 |
| 20140038973 | Compositions and Methods for Eye Whitening - The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine. | 2014-02-06 |
| 20140038974 | Compositions and Methods for Eye Whitening - The invention provides compositions and methods for whitening of eyes and/or reducing redness of eyes. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine, dexmedetomidine, guanfacine or fadolmidine. | 2014-02-06 |
| 20140038975 | Imidazole, Pyrazole, and Triazole Derivatives Useful As Antibacterial Agents - The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections. | 2014-02-06 |
| 20140038976 | PIPERAZINE DERIVATIVES AS CAV2.2 CALCIUM CHANNEL BLOCKERS - The invention relates to novel piperazine compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca | 2014-02-06 |
| 20140038977 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR - The present invention relates to the compounds of general formula I | 2014-02-06 |
| 20140038978 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS - Compounds of formula (I) | 2014-02-06 |
| 20140038979 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 2014-02-06 |
| 20140038980 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE - Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment. | 2014-02-06 |
| 20140038981 | NOVEL EGFR MODULATORS AND USES THEREOF - The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways. | 2014-02-06 |
| 20140038982 | CANCER TREATMENT METHOD - Invented is a method of treating cancer or a pre-cancerous syndrome in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a non-peptide thrombopoietin (TPO) receptor agonist to such mammal, suitably a human. | 2014-02-06 |
| 20140038983 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 2014-02-06 |
| 20140038984 | Compositions and Methods for the Treatment of Metabolic and Related Disorders - The present invention relates to the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. Also provided are methods for the treatment and/or prevention of one or more metabolic disorders, for example, obesity or diabetes, utilizing fatostatin A and/or a derivative and/or analog thereof and/or the A-B-C tripartite compounds. | 2014-02-06 |
| 20140038986 | MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS - The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Human Double Minute inhibitors (MDM2i), methods of determining the sensitivity of a cell to an MDM2i by measuring biomarkers and methods of screening for candidate MDM2i. | 2014-02-06 |
| 20140038987 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases. | 2014-02-06 |
| 20140038988 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD - The present invention relates to novel heterocyclically fused diaryldihydropyrimidine derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system. | 2014-02-06 |
| 20140038989 | TETRAHYDROPYRAZOLO [1,5-A] PYRIMIDINE AS ANTI-TUBERCULOSIS COMPOUNDS - A compound of Formula (I) or a pharmaceutically acceptable salt thereof: | 2014-02-06 |
| 20140038990 | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease - The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 2014-02-06 |
| 20140038991 | Protein Kinase Inhibitors - The present invention is directed to compounds of the Formula I | 2014-02-06 |
| 20140038992 | METHODS OF ADMINISTERING RALTEGRAVIR AND RALTEGRAVIR COMPOSITIONS - The present disclosure is related to amorphous raltegravir and the solid oral dosage forms of amorphous raltegravir that are of lower dosage than the commercially available reference dosage form. | 2014-02-06 |
| 20140038993 | NEW COMPOUNDS - The present invention includes compounds of general formula ( | 2014-02-06 |
| 20140038994 | Salts of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-- 3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes. | 2014-02-06 |
| 20140038995 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor - Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H | 2014-02-06 |
| 20140038996 | Freeze Dried Drug Nanosuspensions - The present invention relates to a freeze-dried (also called lyophilized) drug nanosuspension. The present freeze-dried drug nanosuspension composition has an acceptable stability of the particle size distribution during storage, including long term storage. | 2014-02-06 |
| 20140038997 | PHARMACEUTICAL COMPOSITION OF VINFLUNINE WHICH IS INTENDED FOR PARENTERAL ADMINISTRATION PREPARATION METHOD THEREOF AND USE OF SAME - The invention relates to a pharmaceutical composition of vinflunine in the form of a stable sterile aqueous solution of a water-soluble salt of vinflunine with a pH of between 3 and 4. The invention also relates to the method of preparing said composition and to the use thereof as a parenterally-administered medicament for the treatment of cancer. | 2014-02-06 |
| 20140038998 | STABILIZED TACROLIMUS COMPOSITION - The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus. | 2014-02-06 |
| 20140038999 | Aryl Lactam Kinase Inhibitors - The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1. | 2014-02-06 |
| 20140039000 | LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON - The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | 2014-02-06 |
